CRO Invitro Research Solutions Ltd has been signed to take OP2101 to the first clinical step. This is a safety and bioavailability study on healthy, adult, human subjects that will be conducted beginning Q2-Q3 2022. Preclinical research indicates that OP2101 might benefiting a wide range of inflammatory skin disorders. The continued clinical development will hence proceed with an open-minded view on what main indications to target, including Atopic Dermatitis, Psoriasis and CSU.